Analyst Comparison of Bio-Techne and VivoSim Labs Stock Profiles
What happened
An analysis compared Bio-Techne and VivoSim Labs, two healthcare companies, across several financial metrics. The comparison noted that Bio-Techne has a beta of 1.28, while VivoSim Labs has a beta of 1.45. Research analysts stated that Bio-Techne is more favorable than VivoSim Labs due to its stronger consensus rating and higher probable upside.
From themarketsdaily.com
Why it matters
The comparison provides insight into the risk and valuation profiles of the two companies. Bio-Techne shares are held by 99.0% institutional investors, compared to 8.2% for VivoSim Labs. This information is relevant for market participants evaluating investment opportunities in the healthcare sector.
From themarketsdaily.com
Who's involved
- Bio-TechneHealthcare company whose stock profile was compared in the analysis
- Merck KGaAGerman multinational science and technology company mentioned in connection to Bio-Techne
Keep exploring
The entities involved
-
Bio-Techne
company
-
Europe
terrestrial continent located in north-western Eurasia
-
Middle East
geopolitical region encompassing Egypt and most of Western Asia, including Iran
Related events
- Atlantic Petroleum operates in various European and Middle Eastern markets and is listed on NASDAQ OMX.
- Synchronoss Technologies provides solutions in the Europe region, the Americas region, the Africa region, and the Middle East, and is listed on Nasdaq.
- Gorilla Technology Group Inc. operates across North America and Europe and is listed on the Nasdaq stock exchange.
- Air Astana Group operates in multiple global markets, including Europe, Central Asia, and India, and is listed on international exchanges.
- First Phosphate is aiming for a listing on the Nasdaq Global Market, focusing on building its North American supply chain with anticipated customers in Europe.